Key facts
- Magnus Medical’s last known valuation is $65.0M (Dec 2020).
- It has raised $89.0M across 2 recorded rounds; the latest was Early Stage VC ($49.0M) in May 2025.
- Notable investors include Dolby Family Ventures, JAZZ Venture Partners, Maj Invest, Red Tree Venture Capital, Still Capital Partners.
- Magnus Medical has filed 2 Form Ds with the SEC, most recently May 2025 ($23.7M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Magnus Medical
Funding rounds
2 roundsAbout Magnus Medical
Developer of a brain stimulation technology designed to treat neurological and psychiatric disorders. The company's technology is a novel treatment that has demonstrated profound and rapid results caused by identifiable changes in brain networks, enabling patients to manage their symptoms acutely and restore and sustain mental health.
- Sector
- Healthcare
- HQ
- Burlingame, CA, United States
- Founded
- 2017
- Employees
- 49
- Website
- magnusmedical.com/
- Ownership
- Privately Held (backing)
Magnus Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Magnus Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Magnus Medical in its N-PORT filings yet. We sweep new filings monthly.